Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA

The combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.

Hairdressers are willing to help customers detect skin cancers

(Reuters Health) – Most hair stylists at salons and barber shops may be interested in getting trained to detect skin cancers on the scalp, face and neck, researchers say.

Posted in Melanoma News, Patients, Latest News

Nivolumab Demonstrates Durable Long-term Survival in Patients with Advanced Cancers

Treatment with nivolumab demonstrated durable survival in previously-treated patients with advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC), according to a new study published in JAMA Oncology.

Personalized Vaccine Shows Protective Benefit Against Disease Recurrence in High-Risk Melanoma

A personalized therapeutic cancer vaccine being developed by Elios Therapeutics for patients with high-risk melanoma demonstrated positive results in a phase 2b clinical trial, according to a press release.